title: Prevalence of autoantibodies to cyclic citrullinated peptide in patients with rheumatic diseases other than rheumatoid arthritis: a French multicenter study.
abstract: Our objective was to evaluate the prevalence of autoantibodies to cyclic citrullinated peptides (anti-CCP aAbs) in a cohort of patients with a variety of inflammatory or non-inflammatory rheumatic diseases other than rheumatoid arthritis (RA). Six hundred and nine serum samples were tested for anti-CCP aAbs and for rheumatoid factor (RF) using enzyme-linked immunosorbent assays and immunonephelometry. The prevalence of anti-CCP aAbs and RF reached 10% and 25%, respectively, using the positive cutoff value suggested by the manufacturers. Using a higher cutoff value (50 U/ml) for both aAbs, the prevalence was lower with 6% and 16%, respectively. The specificity of both markers for RA thus reached 94% and 84%, respectively. Anti-CCP aAbs were found to be elevated in inflammatory and also in non-inflammatory rheumatic diseases in the same proportion. Clinical data obtained for 36 positive patients showed that 17% developed RA within 5 years. In conclusion, anti-CCP aAbs are clearly more specific than RF for RA. Follow-up of anti-CCP aAbs-positive patients with inflammatory or non-inflammatory rheumatic diseases other than RA could be important considering the predictive value of these aAbs for the development of RA.
authors.affiliation: Department of Immunology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Inserm U851, 69495, Pierre-Benite Cedex, France. nicole.fabien@chu-lyon.fr
authors.forename: Nicole
authors.initials: N
authors.lastname: Fabien
authors.forename: Nils-Olivier
authors.initials: NO
authors.lastname: Olsson
authors.forename: Joëlle
authors.initials: J
authors.lastname: Goetz
authors.forename: Catherine
authors.initials: C
authors.lastname: Johanet
authors.forename: Andrée
authors.initials: A
authors.lastname: Escande
authors.forename: Nathalie
authors.initials: N
authors.lastname: Bardin
authors.forename: Marielle
authors.initials: M
authors.lastname: Sanmarco
authors.forename: Chantal
authors.initials: C
authors.lastname: Andre
authors.forename: Alain
authors.initials: A
authors.lastname: Chevailler
authors.forename: René-Louis
authors.initials: RL
authors.lastname: Humbel
authors.forename: Pascale
authors.initials: P
authors.lastname: Chretien
authors.forename: Jean-claude
authors.initials: JC
authors.lastname: Monier
authors.forename: Françoise
authors.initials: F
authors.lastname: Fortenfant
authors.forename: Françoise
authors.initials: F
authors.lastname: Oksman
authors.forename: Marie-France
authors.initials: MF
authors.lastname: Taillefer
authors.forename: Jean
authors.initials: J
authors.lastname: Sibilia
mesh_terms: D000368:Aged; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology; D001323:Autoantibodies / Q000097:blood*; D001327:Autoimmune Diseases / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000276:immunology*; D011237:Predictive Value of Tests; D015995:Prevalence; D012216:Rheumatic Diseases / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology; D012217:Rheumatoid Factor / Q000097:blood; D012680:Sensitivity and Specificity
chemical_list: D001323:Autoantibodies; D010456:Peptides, Cyclic; C487763:cyclic citrullinated peptide; D012217:Rheumatoid Factor